Medicaid and Medicare Utilization of Direct-Acting Antiviral Medications for Patients With Hepatitis C

Medicaid and Medicare Utilization of Direct-Acting Antiviral Medications for Patients With Hepatitis C

Saved in:

Bibliographic Details
Main Authors:	Xiaohan Ying, Alexander Zhao, Nicole Ng, Russell Rosenblatt, Catherine Lucero, Arun B. Jesudian
Format:	Article
Language:	English
Published:	Elsevier 2025-01-01
Series:	Gastro Hep Advances
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772572324001791
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C
by: Raymond Anthony Pashun, et al.
Published: (2016-01-01)

Disparities in Medicaid and Medicare physician reimbursements for ophthalmic procedures.
by: Angela R Elam, et al.
Published: (2025-01-01)

Disparities in Medicaid and Medicare physician reimbursements for ophthalmic procedures
by: Angela R. Elam, et al.
Published: (2025-01-01)

Direct Acting Antivirals for the Treatment of Chronic Viral Hepatitis
by: Peter Karayiannis
Published: (2012-01-01)

314 Mapping preeclampsia inequalities in medical treatment: Converging medicare/medicaid and clinical trial availability
by: Olivia Diaz, et al.
Published: (2025-04-01)

Pharmacist-Led Transitions of Care Reduced Hospital Readmission Rates for Medicare and Medicaid Patients
by: Aubrey Baccari, et al.
Published: (2025-07-01)

Direct Acting Antivirals in Patients with Chronic Hepatitis C and Down Syndrome
by: Eric R. Yoo, et al.
Published: (2016-01-01)

Cost-effectiveness of hepatitis C treatment using generic direct-acting antivirals available in India.
by: Rakesh Aggarwal, et al.
Published: (2017-01-01)

Self-reported experience in patients treated with Hepatitis C direct acting antivirals
by: Irene Cañamares Orbis, et al.
Published: (2016-12-01)

Impact of non-medical switching of prescription medications on health outcomes: an e-survey of high-volume medicare and medicaid physician providers
by: Craig Coleman, et al.
Published: (2020-01-01)

Primary hepatic large B-cell lymphoma following direct-acting antiviral treatment for hepatitis C
by: Yosra Zaimi, et al.
Published: (2021-10-01)

Effects of Various Direct-acting Antivirals in the Quality of Life of Patients with Chronic Hepatitis C
by: Hatun ÖZTÜRK ÇERİK, et al.
Published: (2021-12-01)

Treatment of the chronic hepatitis C complicated by mixed cryoglobulinemia with direct-acting antiviral agents
by: N. V. Dunaeva, et al.
Published: (2018-12-01)

The effect of cognitive emotion regulation on direct-acting antivirals adherence in patients with hepatitis C
by: Adina Turcu-Stiolica, et al.
Published: (2024-11-01)

Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
by: Fei Xiao, et al.
Published: (2014-05-01)

Cost–utility of sofosbuvir/velpatasvir versus other direct-acting antivirals for chronic hepatitis C genotype 1b infection in China
by: Haoya Yun, et al.
Published: (2020-08-01)

Utility of a buccal swab point-of-care test for the IFNL4 genotype in the era of direct acting antivirals for hepatitis C virus.
by: Aminata Sy, et al.
Published: (2023-01-01)

Complexity and Variation in Infectious Disease Birth Cohorts: Findings from HIV+ Medicare and Medicaid Beneficiaries, 1999–2020
by: Nick Williams
Published: (2024-11-01)

Medicare Under Age 65 and Medicaid Patients Have Poorer Bowel Preparations: Implications for Recommendations for an Early Repeat Colonoscopy.
by: Bryan B Brimhall, et al.
Published: (2016-01-01)

A Comprehensive Review of Antiviral Therapy for Hepatitis C: The Long Journey from Interferon to Pan-Genotypic Direct-Acting Antivirals (DAAs)
by: Lorenza Di Marco, et al.
Published: (2025-01-01)

Interactions between Immunosuppressive Therapy and Direct-Acting Antivirals in Kidney Transplant Recipient with Hepatitis C Infection
by: Paolo Carta, et al.
Published: (2020-05-01)

Treatment of hepatitis C using direct-acting antiviral (DAA) agents in patients undergoing liver transplantation
by: V. E. Syutkin, et al.
Published: (2016-02-01)

Direct-Acting-Antivirals Anti-hepatitis C Virus in Renal Transplant Patients: Relevance of Pharmacologic Interaction
by: Maurizio Salvadori, et al.
Published: (2020-08-01)

Are there differences in efficacy and safety between local and imported direct-acting antiviral agents for hepatitis C in China?
by: Zhitao Wang, et al.
Published: (2025-07-01)

Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.
by: Autumn Zuckerman, et al.
Published: (2018-01-01)

Estimating the impact of direct acting antiviral therapy on the prevalence of hepatitis C virus infection using phylogenetics
by: Hossain M.S. Sazzad, et al.
Published: (2025-05-01)

Impact of Treatment with Direct Acting Antiviral Drugs on Glycemic Control in Patients with Hepatitis C and Diabetes Mellitus
by: Pradeep Kumar Mada, et al.
Published: (2020-01-01)

The Impact of Medicaid Preferred Drug Lists on Utilization and Costs of Antipsychotic Medication
by: Christian Frois, et al.
Published: (2013-05-01)

Machine Learning Approach to Identifying Wrong-Site Surgeries Using Centers for Medicare and Medicaid Services Dataset: Development and Validation Study
by: Yuan-Hsin Chen, et al.
Published: (2025-02-01)

Effect of Direct-Acting Antiviral Therapy on Thrombocytopenic Patients with Hepatitis C Virus-Related Chronic Liver Disease
by: Mahmoud Saif-Al-Islam, et al.
Published: (2021-01-01)

Sorafenib-treated hepatocellular carcinoma with or without prior direct-acting antiviral therapy for hepatitis C: outcomes and survival
by: Rania Lithy, et al.
Published: (2025-08-01)

Partial restoration of immune response in Hepatitis C patients after viral clearance by direct-acting antiviral therapy.
by: Meritxell Llorens-Revull, et al.
Published: (2021-01-01)

Success of a second treatment of direct-acting antiviral therapy in patients with chronic Hepatitis C Virus infection.
by: Daniela L. Andrade-González, et al.
Published: (2025-04-01)

An ODEs multiscale model with cell proliferation for hepatitis C virus infection treated with direct acting antiviral agents
by: Hesham A. Elkaranshawy, et al.
Published: (2024-12-01)

The Effects of Pangenotypic Direct-Acting Antiviral Therapy on Lipid Profiles and Insulin Resistance in Chronic Hepatitis C Patients
by: Meng-Yu Ko, et al.
Published: (2025-02-01)

Chronic Hepatitis C Infection Treated with Direct-Acting Antiviral Agents and Occurrence/Recurrence of Hepatocellular Carcinoma: Does It Still Matter?
by: Carlo Smirne, et al.
Published: (2024-12-01)

A Path to Better Care for Older Adults: Optimizing Medicare and Medicaid Payments Through Implementation of the CMS Age Friendly Hospital Measure
by: Leslie J. Pelton MPA, et al.
Published: (2025-07-01)

Medicaid Reimbursement for Common Orthopaedic Foot and Ankle Procedures Is Highly Inconsistent Among States, Ranging from 37% to 324% of Medicare Reimbursement
by: Adam P. Henderson BS, et al.
Published: (2025-04-01)

Effects of Medicare Coverage of a “Welcome-to-Medicare” Visit on Use of Preventive Services among New Medicare Enrollees
by: Boon Peng Ng, et al.
Published: (2017-01-01)

Direct-acting antiviral therapy for patients with hepatitis C virus-related hepatocellular carcinoma: A nationwide cohort study
by: Shou-Wu Lee, et al.
Published: (2025-07-01)